For the second quarter of the fiscal year ending March 2027, consolidated revenues were 2,406,997 million yen (Year-over-Year +8.4%, CER basis -1.0%), operating income was 406,739 million yen (CER basis +45.0%), and interim profit was 305,716 million yen. The interim dividend policy continues at 104 yen \u2192 102 yen, and full-year forecasts were revised to revenues of 4,700 hundred million yen, operating income of 453,000 million yen, and net income attributable to owners of parent of 209,000 million yen on a CER basis. Core metrics were also revised upward to Core revenues of 2,406,997 million yen, Core operating income of 710,600 million yen, and Core EPS of 308 yen. Exchange rate effects and investment in new drugs\/new products were key drivers.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4502-20261029-01.pdf","jir_short_summary":"For the second quarter of the fiscal year ending March 2027, consolidated revenues were 2,406,997 million yen (Year-over-Year +8.4%, CER basis -1.0%), operating income was 406,739 million yen (CER basis +45.0%), and interim profit was 305,716 million yen. The interim dividend policy continues at 104 yen \u2192 102 yen, and full-year forecasts were revised to revenues of 4,700 hundred million yen, operating income of 453,000 million yen, and net income attributable to owners of parent of 209,000 million yen on a CER basis. Core metrics were also revised upward to Core revenues of 2,406,997 million yen, Core operating income of 710,600 million yen, and Core EPS of 308 yen. Exchange rate effects and investment in new drugs\/new products were key drivers.","jir_summary":"### Summary of Results\nTakeda Pharmaceutical Company Limited announced consolidated results for the second quarter of the fiscal year ending March 2027. Revenue was 2,406,997 million yen, an increase of 8.4% Year-over-Year (CER basis -1.0%). Operating income was 406,739 million yen, and interim profit was 305,716 million yen, representing substantial increases. By region and product, strength in specific areas continued. Core metrics show Core revenue of 2,406,997 million yen, Core operating income of 710,600 million yen, and Core EPS of 308 yen, indicating growth on a CER basis.\n\n### Dividend and Forecast Updates\nThe interim dividend is maintained at 102 yen\/share, with an expected annual total of 204 yen\/share. The consolidated forecast for the fiscal year ending March 2027 has been revised to revenue of 4,700 hundred million yen, operating income of 453,000 million yen, profit before tax of 270,000 million yen, net income attributable to owners of parent of 209,000 million yen, with upward revisions to Core metrics as well. The outlook factors in exchange rate effects and investment in new drugs and new products, while considering LOE and impacts from mature products.","jir_financial_highlights":"Revenue: 2,406,997 million yen (Year-over-Year +8.4% (CER basis -1.0%))\nOperating Income: 406,739 million yen (Year-over-Year +60.4% (CER basis +45.0%))\nInterim Profit: 305,716 million yen (Year-over-Year +171.6% (CER basis +148.7%))\nInterim Profit per Share: 192.53 yen (Year-over-Year +111.96 yen)\nDividend: Interim dividend 102 yen\/share, Annual total 204 yen\/share (planned) (No change from initial forecast)\nCore Revenue: 2,407,0? million yen (Refer to separate materials for CORE metrics, CER basis change approximately 0)","jir_category":"","jir_hashtags":"#TakedaPharmaceuticalCompanyLimited, #Earnings, #Interim, #NewDrugInvestment, #ExchangeRateImpact","jir_key_figures":"Revenue: 2,406,997 million yen\nOperating Income: 406,739 million yen\nInterim Profit: 305,716 million yen","jir_meta_title":"Takeda Pharmaceutical Company Limited Q2 FY2027 Financial Summary | Revenue 2,406,997 million yen, Operating Income 406,739 million yen","jir_meta_description":"Key takeaways from Takeda Pharmaceutical Company Limited's Q2 FY2027 financial summary. Revenue at the 2.4 trillion yen level, operating income exceeding 406 billion yen, product-level trends, dividend policy, and revisions to full-year forecasts.","jir_og_title":"Takeda Pharmaceutical Company Limited | Q2 FY2027 Financial Summary","jir_og_description":"Takeda Pharmaceutical Company Limited's Q2 results: Revenue 2,406,997 million yen, Operating Income 406,739 million yen. Full-year dividend policy of 204 yen\/share and improvements in Core metrics are indicated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136607","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n